Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.16% of ...
Standard BioTools (LAB) expects fourth quarter 2024 revenue of approximately $46.5M and full year 2024 revenue of approximately $174M. “The ...
Standard BioTools Inc. announced that their Chief Commercial Officer, Jeremy Davis, will step down from his position effective February 1, 2025. The company will enter into a severance agreement ...
In recent trading, Standard Biotools Inc (LAB) stock price has shown some volatility, fluctuating 13.19% over the last five trades and 1 ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue ...
On Monday, shares of Standard BioTools saw a significant surge of 26% following the announcement of their preliminary fourth-quarter revenue. The company that merged with SomaLogic in the previous ...
Investing.com -- Shares of Standard BioTools Inc. (NASDAQ: LAB) surged 30% following the company's announcement of preliminary fourth quarter revenue that exceeded market expectations. The life ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback